Medtronic Announces US Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint

Medtronic (NYSE: MDT ) today announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board (DSMB) concluded that there were no safety concerns in